Progensa™ PCA3 test for prostate cancer detection

Publisher Website
Google Scholar
Abstract
Patients with an elevated serum total prostate-specific antigen value or abnormal digital rectal examination results are at risk of having prostate cancer and should undergo prostate needle biopsies. However, approximately 60% of them will have a negative prostate biopsy result. Therefore, further biopsies are recommended for young patients at risk of prostate cancer with a positive rate of 20-40%. Biomarkers are required in order to avoid unnecessary biopsies. The PCA3 gene product is specifically overexpressed in prostate tumor cells, and modern molecular biology techniques allow us to use a specific test for this gene in order to select patients who have a high risk of having prostate cancer. Literature reviews of the gene product, as well as the first clinical results of the Progensa PCA3 test, are presented.

This publication has 29 references indexed in Scilit: